Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3552 - KRAS mutations (KRAS-mut) and antiPD1/PDL1 therapy in a cohort of non-small cell lung cancer (NSCLC) patients (p). Experience from a single institution.

Date

10 Sep 2017

Session

Poster display session

Topics

Cancers in Adolescents and Young Adults (AYA);  Immunotherapy;  Thoracic Malignancies

Presenters

Carlos Erasun Lecuona

Citation

Annals of Oncology (2017) 28 (suppl_5): v403-v427. 10.1093/annonc/mdx376

Authors

C. Erasun Lecuona1, M.T. Moran Bueno1, L. Vila1, I. Teruel2, L. Angelats2, A. Ferrando2, A. Plaja2, P. Torres3, E. Lopez4, R. Muriel4, A.M. Muñoz-Marmol5, J.L. Mate5, J.M. Velarde6, E. Carcereny Costa1

Author affiliations

  • 1 Medical Oncology, Catalan Institute of Oncology Badalona, Hospital Universitari Germans Trias i Pujol, 08916 - Badalona/ES
  • 2 Medical Oncology, Catalan Institute of Oncology Badalona, Hospital Universitary Germans Trias i Pujol, 08916 - Badalona/ES
  • 3 Medical Oncology And Hematology, Catalan Institute of Oncology Badalona, Hospital Universitary Germans Trias i Pujol, 08916 - Badalona/ES
  • 4 Medical Oncology And Hematology, Catalan Institute of Oncology Badalona, Hospital Universitari Germans Trias i Pujol, 08916 - Badalona/ES
  • 5 Pathology, Hospital Universitari Germans Trias i Pujol, 08916 - Badalona/ES
  • 6 Biostatistics, Hospital Universitari Germans Trias i Pujol, Fundació Institut d' Investigacions en Ciencies de la Salut Germans Trias i Pujol, Catalan Institute of Oncology Badalona, 08916 - Badalona/ES
More

Resources

Abstract 3552

Background

AntiPD1/antiPDL1-based immunotherapy has changed dramatically the prognosis of NSCLC p with a substantial improvement of overall survival (OS) and even presenting long lasting responses in a subset of p. Several factors have been associated with the likelihood of better survival, which include the smoking exposure and the presence of KRAS-mut according to data from randomized clinical trials that compared chemotherapy to these immunotherapeutic agents.

Methods

By reviewing the clinical records of all stage IV NSCLC p treated with antiPD1/antiPDL1 agents, we identified p with KRAS-mut and evaluated their clinical outocomes.

Results

129 p with advanced NSCLC were treated with nivolumab, pembrolizumab or atezolizumab (65.1%, 17.1% and 17.8%, respectively) from November 2013 to April 2017. 14 p were identified as adenocarcinomas with KRAS-mut (20.3%) of all non-squamous NSCLC (60p) once squamous cell carcinoma (39 p), p with Kras status unknown (15p), or due to other reasons (6p) were excluded. Kras-mut subgroup included 28.5% of female, with median age of 62.3 years, 92.8% of ever smokers, and PS0 and 1 in 21.4 and 78.6%, respectively. The immunotherapy consisted of nivolumab (71.4%) and pembrolizumab and atezolizumab (14.3% each) and was administered as 1st, 2nd and ≥3rd therapy in 7.1, 78.6 and 14.3% of p, respectively. 71.4% of p responded to therapy (64.3% were evaluated as partial response) and in 42.8% of p this response lasted ≥12 months (range 12-32). For this cohort of p median progression-free survival was 7.65 months and median OS was 58 months. At the time of analysis 57.1% were still receiving treatment.

Conclusions

Although the number of p is small, KRAS-mut p represent a subgroup of p that seem to substantially benefit from antiPD1/PDL1 agents in terms of both response and survival.

Clinical trial identification

Not applicable

Legal entity responsible for the study

Medical Oncologya Department, Catalan Institute of Oncology Badalona

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.